Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

  title={Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework},
  author={A. Atkinson and W. Colburn and V. DeGruttola and D. Demets and G. Downing and D. Hoth and J. Oates and C. Peck and R. Schooley and B. Spilker and J. Woodcock and S. Zeger},
  journal={Clinical Pharmacology & Therapeutics},
  • A. Atkinson, W. Colburn, +9 authors S. Zeger
  • Published 2001
  • Medicine
  • Clinical Pharmacology & Therapeutics
  • genome are dramatically reshaping the research and development pathways for drugs, vaccines, and diagnostics. The growth in the number of molecular entities entering the drug development pipeline has accelerated as a consequence of powerful discovery and screening technologies such as combinatorial chemistry, mass spectrometry, high throughput screening, celland tissue-based DNA microarrays, and proteomic approaches.1 As a consequence, there is an escalating number of therapeutic candidates… CONTINUE READING
    4,633 Citations

    Topics from this paper

    Paper Mentions

    Observational Clinical Trial
    The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in… Expand
    ConditionsAdrenal Insufficiency, Arrythmia, Asthma in Children, (+17 more)
    Chapter 8 – Biomarkers
    The Biomarkers Consortium: On the Critical Path of Drug Discovery
    • C. A. Altar
    • Medicine
    • Clinical pharmacology and therapeutics
    • 2008
    • 60
    Biomarker Analysis as a Decision-Making Tool in Drug Discovery and Development
    • 4
    Molecular profiling approaches for identifying novel biomarkers.
    • 39
    • Highly Influenced
    • PDF
    Molecular profiling approaches for identifying novel biomarkers
    • Highly Influenced
    Mass spectrometry-based biomarkers in drug development.
    • 12


    Efficacy Measures: Surrogates or Clinical Outcomes?
    • 21
    Meta-analysis for the evaluation of potential surrogate markers.
    • 289
    New molecular endpoints and methods for routine toxicity testing.
    • 40
    Surrogate End Points in Clinical Trials: Are We Being Misled?
    • 1,401
    • PDF
    Surrogate endpoints in clinical trials: definition and operational criteria.
    • 1,621
    DNA Damage as an Intermediate Biomarker in Intervention Studies
    • R. Santella
    • Chemistry, Medicine
    • Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine
    • 1997
    • 37
    Evaluating surrogate markers.
    • M. Hughes, V. DeGruttola, S. Welles
    • Medicine
    • Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association
    • 1995
    • 31